Baidu
map

Cell:单细胞测序新方法研究原发性血小板增多症获进展

2012-03-16 MedSci MedSci原创

近日,国际著名杂志Cell在线刊登了武汉大学生命科学学院研究人员的最新研究成果“Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm,”,文章中,研究者研发出了一种解析单细胞基因组的新方法,该研究同时登上了当期Cell研究的新亮点。 该文章的并列

近日,国际著名杂志Cell在线刊登了武汉大学生命科学学院研究人员的最新研究成果“Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm,”,文章中,研究者研发出了一种解析单细胞基因组的新方法,该研究同时登上了当期Cell研究的新亮点。

该文章的并列第一作者宋卢挺,系首批加入武汉大学——华大基因联合培养创新班的七名同学之一,于2010年3月赴深圳华大基因研究院从事基因组学研究工作。联合培养期间,宋卢挺充分利用华大基因研究院作为全球最大基因组学研究中心的平台优势,积极把握各种学习和锻炼的机会,在2010年的第五届国际基因组大会(ICG-V)上作主题报告,最终成长为华大基因研究院癌症单细胞研究的负责人。

在本项研究中,以宋卢挺为项目负责人的研究团队研发了一种解析单细胞基因组的新方法,并将该方法应用于原发性血小板增多症(ET)的肿瘤内部遗传特征研究,在肿瘤研究上获得突破性进展。

此单细胞测序新方法是遗传异质性肿瘤的高精度、全面评估的一个非常优秀的研究工具,为从单核苷酸水平深入研究癌症发生、发展机制及其诊断、治疗提供了新的研究思路。这种新方法和产生的数据为鉴定与肿瘤发展相关的候选基因提供了科学依据,也必将会推动癌症的遗传机理和生物学过程更深入的研究。此外,这一新方法还可被广泛用于其他重要的生物研究领域,如组织器官内细胞基因组的异质性研究、干细胞的异质性研究、生殖细胞的遗传重组研究、胚胎的植入前遗传学诊断研究等

原始链接:

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903008, encodeId=1a05190300813, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Fri Sep 28 11:10:00 CST 2012, time=2012-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028497, encodeId=392c202849edf, content=<a href='/topic/show?id=b3eb890300a' target=_blank style='color:#2F92EE;'>#血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89030, encryptionId=b3eb890300a, topicName=血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 18 03:10:00 CST 2012, time=2012-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846430, encodeId=81181846430cf, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 20 15:10:00 CST 2012, time=2012-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868469, encodeId=cdee186846936, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jul 09 06:10:00 CST 2012, time=2012-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958682, encodeId=b5061958682a1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 19 03:10:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573024, encodeId=829315e302417, content=<a href='/topic/show?id=9c143e122ef' target=_blank style='color:#2F92EE;'>#原发性血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37122, encryptionId=9c143e122ef, topicName=原发性血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f86c15802806, createdName=weihongyv, createdTime=Sun Mar 18 01:10:00 CST 2012, time=2012-03-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903008, encodeId=1a05190300813, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Fri Sep 28 11:10:00 CST 2012, time=2012-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028497, encodeId=392c202849edf, content=<a href='/topic/show?id=b3eb890300a' target=_blank style='color:#2F92EE;'>#血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89030, encryptionId=b3eb890300a, topicName=血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 18 03:10:00 CST 2012, time=2012-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846430, encodeId=81181846430cf, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 20 15:10:00 CST 2012, time=2012-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868469, encodeId=cdee186846936, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jul 09 06:10:00 CST 2012, time=2012-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958682, encodeId=b5061958682a1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 19 03:10:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573024, encodeId=829315e302417, content=<a href='/topic/show?id=9c143e122ef' target=_blank style='color:#2F92EE;'>#原发性血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37122, encryptionId=9c143e122ef, topicName=原发性血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f86c15802806, createdName=weihongyv, createdTime=Sun Mar 18 01:10:00 CST 2012, time=2012-03-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903008, encodeId=1a05190300813, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Fri Sep 28 11:10:00 CST 2012, time=2012-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028497, encodeId=392c202849edf, content=<a href='/topic/show?id=b3eb890300a' target=_blank style='color:#2F92EE;'>#血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89030, encryptionId=b3eb890300a, topicName=血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 18 03:10:00 CST 2012, time=2012-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846430, encodeId=81181846430cf, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 20 15:10:00 CST 2012, time=2012-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868469, encodeId=cdee186846936, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jul 09 06:10:00 CST 2012, time=2012-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958682, encodeId=b5061958682a1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 19 03:10:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573024, encodeId=829315e302417, content=<a href='/topic/show?id=9c143e122ef' target=_blank style='color:#2F92EE;'>#原发性血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37122, encryptionId=9c143e122ef, topicName=原发性血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f86c15802806, createdName=weihongyv, createdTime=Sun Mar 18 01:10:00 CST 2012, time=2012-03-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1903008, encodeId=1a05190300813, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Fri Sep 28 11:10:00 CST 2012, time=2012-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028497, encodeId=392c202849edf, content=<a href='/topic/show?id=b3eb890300a' target=_blank style='color:#2F92EE;'>#血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89030, encryptionId=b3eb890300a, topicName=血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 18 03:10:00 CST 2012, time=2012-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846430, encodeId=81181846430cf, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 20 15:10:00 CST 2012, time=2012-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868469, encodeId=cdee186846936, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jul 09 06:10:00 CST 2012, time=2012-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958682, encodeId=b5061958682a1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 19 03:10:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573024, encodeId=829315e302417, content=<a href='/topic/show?id=9c143e122ef' target=_blank style='color:#2F92EE;'>#原发性血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37122, encryptionId=9c143e122ef, topicName=原发性血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f86c15802806, createdName=weihongyv, createdTime=Sun Mar 18 01:10:00 CST 2012, time=2012-03-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1903008, encodeId=1a05190300813, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Fri Sep 28 11:10:00 CST 2012, time=2012-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028497, encodeId=392c202849edf, content=<a href='/topic/show?id=b3eb890300a' target=_blank style='color:#2F92EE;'>#血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89030, encryptionId=b3eb890300a, topicName=血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 18 03:10:00 CST 2012, time=2012-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846430, encodeId=81181846430cf, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 20 15:10:00 CST 2012, time=2012-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868469, encodeId=cdee186846936, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jul 09 06:10:00 CST 2012, time=2012-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958682, encodeId=b5061958682a1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 19 03:10:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573024, encodeId=829315e302417, content=<a href='/topic/show?id=9c143e122ef' target=_blank style='color:#2F92EE;'>#原发性血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37122, encryptionId=9c143e122ef, topicName=原发性血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f86c15802806, createdName=weihongyv, createdTime=Sun Mar 18 01:10:00 CST 2012, time=2012-03-18, status=1, ipAttribution=)]
    2012-08-19 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1903008, encodeId=1a05190300813, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Fri Sep 28 11:10:00 CST 2012, time=2012-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028497, encodeId=392c202849edf, content=<a href='/topic/show?id=b3eb890300a' target=_blank style='color:#2F92EE;'>#血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89030, encryptionId=b3eb890300a, topicName=血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 18 03:10:00 CST 2012, time=2012-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846430, encodeId=81181846430cf, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 20 15:10:00 CST 2012, time=2012-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868469, encodeId=cdee186846936, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jul 09 06:10:00 CST 2012, time=2012-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958682, encodeId=b5061958682a1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Aug 19 03:10:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573024, encodeId=829315e302417, content=<a href='/topic/show?id=9c143e122ef' target=_blank style='color:#2F92EE;'>#原发性血小板增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37122, encryptionId=9c143e122ef, topicName=原发性血小板增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f86c15802806, createdName=weihongyv, createdTime=Sun Mar 18 01:10:00 CST 2012, time=2012-03-18, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map